Fig. 1

6562618

x x x x x x x x x x x x x x x x x x x
x v 0 000 000 000 000 000 000 000 000 00
××0 000 ××× 000 ××× × × × × × × × × × ×
xv0 000 xxx
××× 000 000 ×××




Fig. 2



Activity of	Inhibiting the	Proliferation of	NKN Cells	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Activity of	Inhibiting the	Binding of	NKN CEIIS	×			×		×		0		0	0			×				×						×	0	×	×		×
	Epitope	Mapping		A	(B)	В	В	В	•	•	B/C	B/(C)	(a)	D	A-/B/C	A-/B	A-/B/C	В	Q	В	A-/B	В	Ω	В	A-/B	D	В	B/C	В	A-/B	A-/B	B/C
	. I	Rat CTGF	,	×00	VΦO	×××	×VO	Oxx	000	×00	××O	Oxx	×∇O	×∇O	××∇	000	××∇	OA×		000	ΟΔ×	·		× 00	× O	× O	000			×∇O	×∇O	×ΦΟ
	Crossreactivity	Mouse	5 0	000	000	× O	000	×00	000	000	×00	×00	×00	×00	×∇O	000	×∇O	000		000	000			000	×∇O	×∇O	000	-		×00	×00	× 00
		Human	5 0	000	000	000	000	000	000	000	000	000	×00	×00	700 -	000	000	000		000	000			× 00	× O	×00	000			00₽	×00	00₽
	sotype			IgG2/ к	IgG2/ κ	IgG2/ к	IgG2/ κ	lgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ ĸ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ ĸ	IgG2/ κ	IgG2/ к	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ	IgG2/ κ
	Antigen			human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF	human CTGF
	Immunized Animal		十	human antibody-producing mouse	human antibody-producing mouse			human antibody-producing mouse	human antibody-producing mouse	human antibody-producing mouse			human antibody-producing mouse	human antibody-producing mouse	human antibody-producing mouse		human antibody-producing mouse	human antibody-producing mouse				human antibody-producing mouse		human antibody-producing mouse	human antibody-producing mouse	human antibody-producing mouse	human antibody-producing mouse					
Ę	Clone name			A4.3	A11.1	A15.1	A29.6	B13.7	B22.2	B29.6	B35.1	C26.11	C59.1	C114.4	M32.2	M33.3	M84.4	M107.2	M122	M124.6	M194.2	M244	M255	M268.1	M288.5	M291.2	M295.2	M315	M320.2	N45.2	N50.1	N60.1


APPROVED O.G. FIG. None
BY OF CLASS SUBCLASS
DRAFTSMAN 435 334

3/25

Fig. 3

. 17.2 –


Fig. 4



USEEDZ7 . USIZIO

Fig. 5


DGSSEZZ/ DGIGIC



Fluorescence Intensity

Fig. 6


ngskitz, ngleno



Fluorescence Intensity:

Fig. 7

USSEZZY LUSICI




Fluorescence Intensity



Human CTGF (ng/well)


5 5 1



Fluorescence Intensity



DAPETEL 'A LEAD



Fluorescence Intensity




Fig. 11

ISEESS OSISIC




Fig. 12





Fig. 13



DGSEIST DG1800





Fig. 14







Fig. 15

[3H] Thymidine uptake







Fig. 16



APPROVED O.G. FIG. Nove BYV: CLASS SUBCLASS DRAFTSMAN 435 326

Fig. 17






Fig. 18






Fig. 19




COSEST. CETSON

Fig. 20



DSSC37.OS1800

Fig. 21



DOSEES, DOLECO




Fig. 22





Fig. **23**.

DYNEESV. OGISIC



; p<0.1





Fig. 24





25/25

Fig. 25

